Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB intends to conduct a head-to-head clinical trial to evaluate the effectiveness of Cimzia (certolizumab pegol) and Humira (adalimumab) as a treatment for moderate to severe rheumatoid arthritis (RA).
Subscribe to our email newsletter
In the study, the patients will be randomized to either certolizumab pegol plus methotrexate (MTX) or adalimumab plus MTX for 12 weeks.
Following this, the patients who will respond will be eligible to continue on their treatment.
Non-responders will switch to the alternative treatment arm until study end at 104 weeks.
The study aims to enroll patients with moderate-to-severe RA who have inadequately responded to MTX and who have not previously received anti-TNF treatment.
UCB chief medical officer Iris Loew-Friedrich said they believe the study will provide additional evidence that the ability to make an informed and early treatment decision is important for the treatment of this severe and progressing disease.